GLP-1 receptor agonists and cardiovascular outcome trials: An update
Major cardiovascular (CV) outcome trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are currently available. These agonists have proven their CV safety, in harmony with the US Food and Drug Administration (FDA) recommendation for antidiabetic drugs. The potential cardioprotective eff...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-11-01
|
| Series: | Hellenic Journal of Cardiology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1109966618304081 |